



## Dicerna to Present at the Jefferies 2018 Global Healthcare Conference

May 29, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 29, 2018-- [Dicerna Pharmaceuticals, Inc.](#) (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate update at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 2:30 p.m. ET. The conference will be held June 5-8, 2018 at the Grand Hyatt in New York City.

A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at [www.dicerna.com](http://www.dicerna.com). An archived replay of the webcast will be available on the Company's website after the conference.

### About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit [www.dicerna.com](http://www.dicerna.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180529005172/en/>

Source: Dicerna Pharmaceuticals, Inc.

### Investors:

Rx Communications Group  
Paula Schwartz, 917-322-2216  
[pschwartz@rxir.com](mailto:pschwartz@rxir.com)

or

### Media:

SmithSolve  
Alex Van Rees, 973-442-1555 ext. 111  
[alex.vanrees@smithsolve.com](mailto:alex.vanrees@smithsolve.com)